Company Overview - ResMed (RMD) is a notable stock within the Medical sector, which consists of 929 individual stocks and ranks 10 in the Zacks Sector Rank [2] - ResMed currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Analysis - Year-to-date, ResMed has achieved a return of approximately 7%, outperforming the average gain of 6.3% for the Medical sector [4] - In comparison, Compass Therapeutics, Inc. (CMPX) has returned 14.7% year-to-date, also outperforming the sector [4] - ResMed is part of the Medical - Products industry, which includes 82 companies and currently ranks 155 in the Zacks Industry Rank; this industry has seen an average loss of 5.6% year-to-date, further highlighting ResMed's strong performance [5] Industry Context - The Medical - Biomedical and Genetics industry, which includes Compass Therapeutics, consists of 450 stocks and is currently ranked 90, with a year-to-date increase of 21.1% [6] - Investors are encouraged to monitor both ResMed and Compass Therapeutics for their continued strong performance in the Medical sector [6]

Compass Therapeutics, Inc. (CMPX) closed the last trading session at $6.19, gaining 20.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.23 indicates an 113.7% upside potential.The mean estimate comprises 13 short-term price targets with a standard deviation of $6.47. While the lowest estimate of $8.00 indicates a 29.2% increase from the current price level, the most optimisti ...

I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wro ...

We came across a bullish thesis on Compass Therapeutics, Inc. on r/stocks by  Cute_Confidence6033. In this article, we will summarize the bulls’ thesis on CMPX. Compass Therapeutics, Inc.'s share was trading at $5.70 as of January 16th. Taysha Gene Therapies Inc. (TSHA) is ‘Market Perform’ on Rett Syndrome Therapy: JMP Securities Compass Therapeutics (CMPX) is a clinical-stage oncology company with a focused pipeline targeting large, underserved cancer markets, and its current valuation appears disconnec ...

Core Viewpoint - Compass Therapeutics is a monoclonal antibody discovery and development company focused on oncology, with significant advancements in its drug pipeline, including positive efficacy signals for its drugs in clinical trials [2][3]. Group 1: Company Overview - Compass Therapeutics is based in Boston, Massachusetts, and specializes in monoclonal antibody development for cancer treatment [2]. - The company has three drugs currently in clinical trials and plans to introduce a fourth drug this quarter [2]. Group 2: Pipeline and Clinical Trials - The most advanced program is Tovecimig, a DLL4 VEGF-A bispecific antibody, which is a next-generation angiogenesis inhibitor [3]. - Tovecimig recently achieved the primary endpoint in a randomized study involving patients with advanced biliary tract cancer [3]. - Data from a Phase II study of Tovecimig in patients with very advanced colorectal cancer was presented at ASCO GI, demonstrating unequivocal monotherapy efficacy [4].

Summary of Compass Therapeutics FY Conference Call Company Overview - **Company**: Compass Therapeutics (NasdaqCM:CMPX) - **Industry**: Oncology, specifically monoclonal antibody discovery and development - **Location**: Boston, Massachusetts - **Pipeline**: Four drugs in clinical development, with Tevesemig being the most advanced Key Points on Tevesemig - **Drug Description**: Tevesemig is a DLL4 VEGF A bispecific antibody, functioning as a next-generation angiogenesis inhibitor [1] - **Clinical Trials**: - Achieved primary endpoint in a randomized study for advanced biliary tract cancer [2] - Presented phase II data at ASCO GI showing monotherapy efficacy in advanced colorectal cancer [2] - Ongoing study COMPANION-002 comparing Tevesemig plus paclitaxel to paclitaxel alone in second-line treatment for advanced biliary tract cancer [6] - **Efficacy Data**: - Tevesemig tripled the overall response rate compared to control, with a complete response noted [7] - Significant difference in progression-free survival (PFS) observed, with 42.1% progression in control vs. 16.2% in combination arm at week eight [9] - More than 20% of patients alive at 18 months, compared to less than 10% in FOLFOX regimen [10] - **Market Opportunity**: - Estimated 25,000 new patients annually in the U.S. with biliary tract cancer, with a treatable population of approximately 15,000 [11] - Potential for over $1 billion annual market in second-line biliary tract cancer [11] - **Future Plans**: - Plans to expand indications post-approval, targeting other cancers like colorectal and gastric [12] - Potential to replace Avastin in various indications [13] Other Drug Developments - **CTX471**: - A CD137 agonist antibody showing nearly 30% response rate in post-PD1 melanoma patients [15] - Notable case of a patient with metastatic small cell lung cancer achieving a complete response after multiple therapies [16] - Planning an NCAM-positive basket study to explore efficacy further [17] - **CTX8371**: - A PD1/PDL1 bispecific antibody demonstrating unique T cell engagement and potential to convert PD1-positive T cells to PD1-negative [19] - Responses observed in patients with triple-negative breast cancer and Hodgkin's lymphoma [21] - Ongoing cohort expansions for further evaluation [21] - **CTX10726**: - A novel PD1/VEGF-A bispecific antibody entering clinical trials, showing superior preclinical efficacy compared to leading competitors [22][38] - Expected to initiate phase 1 study this quarter, with clinical data anticipated in the second half of the year [40] Commercialization Strategy - **Tevesemig**: - Plans to commercialize independently in the U.S. due to the specialized nature of the patient population [31] - Open to strategic partnerships for international markets [32] - **Infrastructure Development**: - Building commercial infrastructure over the next 12-18 months in preparation for drug launch [36] Conclusion - Compass Therapeutics is positioned for significant growth with its innovative pipeline, particularly Tevesemig, which has the potential to transform treatment for advanced biliary tract cancer and other malignancies. The company is actively preparing for commercialization and exploring further clinical opportunities across its drug portfolio.

Market Overview - U.S. stocks showed mixed performance, with the Dow Jones index declining approximately 0.2% on Wednesday [1] Company Highlights - Monte Rosa Therapeutics Inc (NASDAQ:GLUE) experienced a significant increase in share price, rising 45.2% to $23.25 after announcing interim data from a Phase 1 clinical study for MRT-8102 [1] - Ventyx Biosciences Inc (NASDAQ:VTYX) shares surged 37.5% to $13.82 following reports of advanced acquisition talks with Eli Lilly & Co. (NYSE:LLY) for over $1 billion [2] - Neumora Therapeutics Inc (NASDAQ:NMRA) saw a rise of 24.7% to $2.27 [2] - Regencell Bioscience Holdings Ltd (NASDAQ:RGC) increased by 21.1% to $40.00 [2] - Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25, with Piper Sandler initiating coverage with an Overweight rating and a price target of $5 [2] - Anywhere Real Estate Inc (NYSE:HOUS) gained 15.6% to $16.71 [2] - AXT Inc (NASDAQ:AXTI) increased by 13.8% to $22.96 [2] - Immuneering Corp (NASDAQ:IMRX) rose 13.1% to $7.60 [2] - Compass Therapeutics Inc. (NASDAQ:CMPX) gained 13.1% to $5.56 [2] - MBX Biosciences Inc (NASDAQ:MBX) rose 11.2% to $31.90 [2] - Rezolve AI PLC (NASDAQ:RZLV) increased by 10.8% to $3.36 [2] - United Microelectronics Corp (NYSE:UMC) gained 10.4% to $8.96 after reporting sales growth for December and the full year [2] - PBF Energy Inc (NYSE:PBF) rose 9.2% to $29.73 [2] - Navan Inc (NASDAQ:NAVN) increased by 8.3% to $18.42 [2] - Ascentage Pharma Group International (NASDAQ:AAPG) gained 8.3% to $28.17 after announcing IND clearance for BTK Degrader APG-3288 by the U.S. FDA [2] - Intel Corp (NASDAQ:INTC) rose 6.4% to $42.60 as the company is enhancing its gaming strategy by developing a new chip for handheld gaming devices [2]

Financial Position - As of December 31, 2025, Compass Therapeutics, Inc. estimated cash, cash equivalents, and marketable securities to be approximately $209 million[6] - The reported amount is unaudited and preliminary, subject to changes upon completion of financial closing procedures[6] - The financial statements for the year ended December 31, 2025, will reflect the finalized amounts[6] Corporate Information - The company provided a corporate update in a press release dated January 6, 2026[5] - The company is listed on the NASDAQ Capital Market under the trading symbol CMPX[2] - The company’s principal executive offices are located in Boston, Massachusetts[1] Company Classification and Compliance - The report indicates that Compass Therapeutics is not currently classified as an emerging growth company[3] - The company has not elected to use the extended transition period for complying with new or revised financial accounting standards[3] Performance and Future Guidance - The report does not provide specific performance metrics or future guidance at this time[4] - There are no details on new products, technologies, market expansion, or mergers and acquisitions in the current report[4]

Core Insights - Compass Therapeutics is advancing multiple first-in-class bispecific antibodies and expects to achieve major data-driven milestones in 2026 [2] - The company has strengthened its management team with the addition of Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer [2] Pipeline Highlights - Key survival analyses for tovecimig in late Q1 2026 could transform treatment for patients with biliary tract cancer [3] - The ongoing Phase 2/3 COMPANION-002 study of tovecimig is on track for late Q1 2026, focusing on progression-free survival (PFS) and overall survival (OS) [5] - CTX-8371 has shown robust responses in patients with solid and hematologic malignancies, with cohort expansions now open for enrollment in triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) [5][11] - Initial data from the Phase 1 study of CTX-10726 is expected in H2 2026, with the study initiation anticipated in Q1 2026 [5][11] Financial Position - As of December 31, 2025, Compass Therapeutics reported an estimated $209 million in cash and marketable securities, providing a cash runway into 2028 [12]

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted non-qualified stock options to purchase 1,000,000 shares o ...